Skip to main content
Fig. 2 | Cell & Bioscience

Fig. 2

From: Loss of TTC17 promotes breast cancer metastasis through RAP1/CDC42 signaling and sensitizes it to rapamycin and paclitaxel

Fig. 2

TTC17 is downregulated in breast cancer tissue, and low TTC17 expression predicts worse clinical outcomes. a Pancancer analysis of TTC17 expression using data from TCGA combined with the GTEx database. b–d Kaplan‒Meier curves of relapse-free survival in patients with ovarian cancer (b), testicular germ cell tumor (c), or kidney renal papillary cell carcinoma (d), stratified by TTC17 expression. Data were obtained from the KM plotter program. e–i Association of TTC17 mRNA expression with primary lesion (T stage, e), lymph node involvement (N stage, f), distant metastasis (M stage, g), clinical stage (h), or molecular subtype (i) in breast cancer patients based on bulk RNA-seq data archived in TCGA. j TTC17 expression level in breast cancer with distinct molecular subtypes using single-cell RNA-seq data from the PanglaoDB project. k TTC17 expression in luminal or basal/TN breast cancer cell lines based on the CCLE dataset. *P < 0.05, **P < 0.01, ***P < 0.001. TCGA, The Cancer Genome Atlas; GTEx, Genotype-Tissue Expression; RNA-seq, RNA-sequencing; CCLE, Cancer Cell Line Encyclopedia

Back to article page